Printer Friendly
The Free Library
14,652,131 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Oculus Innovative Sciences to Announce Fiscal Third Quarter 2007 Results on Wednesday, February 21.


To Present at Roth Conference February 21

PETALUMA, Calif. -- Oculus oculus

(Latin: “eye”) In architecture, any of several elements resembling an eye, such as a round or oval window or the round opening at the top of some domes (see Pantheon).
 Innovative Sciences, Inc. (Nasdaq: OCLS OCLS Off-Campus Library Services ) announced that it will release financial results for its third fiscal quarter ended December 31, 2006, on February 21, 2007 before market open.

The Company will present at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services,  Annual OC Conference in Dana Point, California Dana Point is a city located in southern Orange County, California. The population was 35,110 at the 2000 census. As one of the few harbors along the Orange County coast, and with ready access via California State Route 1, it is a popular local destination for surfing and is home  on February 21 at 9:30 am Pacific Time. Hoji Alimi, president and chief executive officer, will discuss the Company and most recent quarter during that presentation which will be web cast.

To access a live audio webcast of Mr. Alimi's presentation, please log on to Oculus Innovative Sciences' website at http://www.oculusis.com approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available on the web site for approximately 90 days following the presentation.

About Oculus

Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in acute and chronic wounds. Oculus' products based on its Microcyn Technology have received CE Mark, or European Union certification, for wound cleaning and reduction of microbial microbial

pertaining to or emanating from a microbe.


microbial digestion
the breakdown of organic material, especially feedstuffs, by microbial organisms.
 load, three U.S. FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 510(k) clearances as a medical device in wound cleaning, lubricating, moistening and dressing, and has been granted additional approvals in Canada, India and Mexico.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Date:Feb 20, 2007
Words:275
Previous Article:Oculus Innovative Sciences, Inc. Announces Exercise of Underwriters' Over-Allotment Option.
Next Article:XIFIN Expands its Presence Among Top U.S. Labs by Partnering with Leading Esoteric Reference Laboratory.



Related Articles
Oculus Innovative Sciences, Inc. Announces Initial Public Offering.
McCormick & Schmick's Seafood Restaurants, Inc. to Announce Fourth Quarter 2006 Results on February 14, 2007.(Financial report)
Oculus Innovative Sciences and Dancohr B.V. Enter Exclusive Distribution Agreement.
Oculus Innovative Sciences, Inc. Announces Exercise of Underwriters' Over-Allotment Option.
Oculus Innovative Sciences Announces Fiscal Third Quarter 2007 Results.(Financial report)
Oculus Announces Initial Sites for Phase II Clinical Trial of Microcyn(R) Technology in Treatment of Mild Diabetic Foot Infections.
China Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute Oculus' Microcyn(R)-Based Wound Care Solution in China.(Medical condition overview)
Oculus Innovative Sciences to Present at Rodman & Renshaw Global Healthcare Conference.
Oculus Innovative Sciences Microcyn(R) Technology Presented in Poster at European Wound Management Association Conference.
Oculus Initiates Patient Enrollment in Phase II Study of Microcyn(R) Technology for Treatment of Mild Diabetic Foot Infections.(Clinical report)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles